205 related articles for article (PubMed ID: 26886647)
1. Outcomes of Induction Chemotherapy for Head and Neck Cancer Patients: A Combined Study of Two National Cohorts in Taiwan.
Chen JH; Yen YC; Liu SH; Yuan SP; Wu LL; Lee FP; Lin KC; Lai MT; Wu CC; Chen TM; Chang CL; Chow JM; Ding YF; Lin MC; Wu SY
Medicine (Baltimore); 2016 Feb; 95(7):e2845. PubMed ID: 26886647
[TBL] [Abstract][Full Text] [Related]
2. Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index.
Chen JH; Yen YC; Yang HC; Liu SH; Yuan SP; Wu LL; Lee FP; Lin KC; Lai MT; Wu CC; Chen TM; Chang CL; Chow JM; Ding YF; Wu SY
Medicine (Baltimore); 2016 Apr; 95(14):e3268. PubMed ID: 27057882
[TBL] [Abstract][Full Text] [Related]
3. Dementia Risk in Irradiated Patients With Head and Neck Cancer.
Chen JH; Yen YC; Liu SH; Lee FP; Lin KC; Lai MT; Wu CC; Chen TM; Yuan SP; Chang CL; Wu SY
Medicine (Baltimore); 2015 Nov; 94(45):e1983. PubMed ID: 26559280
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
[TBL] [Abstract][Full Text] [Related]
5. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
6. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
7. Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes.
Chang JH; Wu CC; Yuan KS; Wu ATH; Wu SY
Oncotarget; 2017 Aug; 8(33):55600-55612. PubMed ID: 28903447
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
9. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Paccagnella A; Ghi MG; Loreggian L; Buffoli A; Koussis H; Mione CA; Bonetti A; Campostrini F; Gardani G; Ardizzoia A; Dondi D; Guaraldi M; Cavallo R; Tomio L; Gava A;
Ann Oncol; 2010 Jul; 21(7):1515-1522. PubMed ID: 20032123
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
11. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer.
Kim KR; Shim HJ; Hwang JE; Cho SH; Chung IJ; Park KS; Kang SR; Kwon SY; Chung WK; Bae WK
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):170-178. PubMed ID: 28940101
[TBL] [Abstract][Full Text] [Related]
12. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.
Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC
Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706
[No Abstract] [Full Text] [Related]
13. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
18. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer.
Lee KW; Koh Y; Kim SB; Shin SW; Kang JH; Wu HG; Sung MW; Keam B; Kim DW; Kim TM; Kim KH; Kwon TK; Hah JH; Kim IA; Ahn SH; Yoon DH; Lee SW; Kim SY; Nam SY; Jung KY; Baek SK; Hong SH; Lee SH; Heo DS
Oncologist; 2015 Oct; 20(10):1119-20. PubMed ID: 26304911
[TBL] [Abstract][Full Text] [Related]
20. Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis.
Stokes WA; Amini A; Jones BL; McDermott JD; Raben D; Ghosh D; Goddard JA; Bowles DW; Karam SD
Head Neck; 2017 Jun; 39(6):1113-1121. PubMed ID: 28301079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
